Haemonetics Corporation announced the appointment of Christopher Simon as President and Chief Executive Officer of the Company.
Chris, who currently serves as a Senior Partner of McKinsey & Company where he leads the Global Medical Products Practice, will assume his duties on May 16, 2016.
“With over twenty years of experience consulting in the medical device and pharmaceutical industries, Chris has a proven track record of helping businesses transform and grow,” the Haemonetics Board of Directors said in a statement. “Under Chris’ leadership, we are confident that the Company will grow and innovate to serve our customers worldwide.”
Chris will succeed Ronald Gelbman, who had been serving as interim Chief Executive Officer since September of 2015. Gelbman will continue to serve as a member of the Haemonetics Board of Directors.
“Haemonetics has such a well-earned reputation in plasma collection, donor centers and hospitals, and I am honored to have been chosen to lead this Company,” Simon said. “I look forward to advancing the strategic plan developed with the Haemonetics leadership team and Board of Directors to drive Haemonetics towards a bright future.”
Simon has been the Lead Partner for McKinsey & Company’s current strategy review with Haemonetics providing him with insight into the current state of the business as well as the strategies for the future of Haemonetics. He has been with McKinsey & Company since 1993, prior to that, he served in commercial roles with Baxter Healthcare Corporation.
Thermo Fisher Scientific has acquired Novasep’s viral vector manufacturing business in Belgium, Henogen, for about €725m ($874.5m) in cash. Henogen offers biotechnology firms, as well as biopharma customers contract manufacturing services for vaccines and therapies.
Research and development group of Eli Lilly and Company, Loxo Oncology at Lilly, and clinical-stage oncology company Merus have announced a research collaboration and exclusive license agreement to develop T-Cell re-directing bispecific antibodies.
Chinese cancer biotech Adagene has filed to raise up to $125 million in a Nasdaq IPO. The listing will give Adagene the means to run early-phase clinical trials of antibodies against CD137 and CTLA-4.